Literature DB >> 35218667

TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.

Hong Yao1, Wanqun Xie1, Yuting Dai2, Yanting Liu1, Weiting Gu1, Jianfeng Li2, Liang Wu2, Jing Xie3, Weiwei Rui3, Bohan Ren4, Li Xue1, Yijun Cheng1, Shaojian Lin1, Changsheng Li1, Hao Tang1, Yu Wang5, Meiqing Lou6, Xiaobiao Zhang7, Ronggui Hu8, Hanbing Shang1, Jinyan Huang2, Zhe Bao Wu1,4.   

Abstract

BACKGROUND: Pituitary neuroendocrine tumors (PitNETs) are common intracranial tumors that are classified into seven histological subtypes, including lactotroph, somatotroph, corticotroph, thyrotroph, gonadotroph, null cell, and plurihormonal PitNETs. However, the molecular characteristics of these types of PitNETs are not completely clear.
METHODS: A total of 180 consecutive cases of PitNETs were collected to perform RNA sequencing. All subtypes of PitNETs were distinguished by unsupervised clustering analysis. We investigated the regulation of TPIT by TRIM65 and its effects on ACTH production and secretion in ACTH-secreting pituitary cell lines, as well as in murine models using biochemical analyses, confocal microscopy, and luciferase reporter assays.
RESULTS: A novel subtype of PitNETs derived from TPIT lineage cells was identified as with normal TPIT transcription but with lowered protein expression. Furthermore, for the first time, TRIM65 was identified as the E3 ubiquitin ligase of TPIT. Depending on the RING domain, TRIM65 ubiquitinated and degraded the TPIT protein at multiple Lys sites. In addition, TRIM65-mediated ubiquitination of TPIT inhibited POMC transcription and ACTH production to determine the fate of the novel subtype of PitNETs in vitro and in vivo.
CONCLUSION: Our studies provided a novel classification of PitNETs and revealed that the TRIM65-TPIT complex controlled the fate of the novel subtype of PitNETs, which provides a potential therapy target for Cushing's disease.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cushing’s disease; PitNETs; TPIT; TRIM65; ubiquitination

Mesh:

Substances:

Year:  2022        PMID: 35218667      PMCID: PMC9340636          DOI: 10.1093/neuonc/noac053

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  29 in total

Review 1.  Ubiquitin and proteasomes in transcription.

Authors:  Fuqiang Geng; Sabine Wenzel; William P Tansey
Journal:  Annu Rev Biochem       Date:  2012-03-08       Impact factor: 23.643

2.  Ubiquitylation of autophagy receptor Optineurin by HACE1 activates selective autophagy for tumor suppression.

Authors:  Zhengzhao Liu; Peng Chen; Hong Gao; Yu Gu; Jiao Yang; Hong Peng; Xingxing Xu; Haifeng Wang; Meiqiang Yang; Xiaoying Liu; Libin Fan; Shiyao Chen; Jian Zhou; Yihong Sun; Kangchen Ruan; Shuqun Cheng; Masaaki Komatsu; Eileen White; Lin Li; Hongbin Ji; Daniel Finley; Ronggui Hu
Journal:  Cancer Cell       Date:  2014-07-14       Impact factor: 31.743

Review 3.  Pituitary-Tumor Endocrinopathies.

Authors:  Shlomo Melmed
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

4.  A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins.

Authors:  B Lamolet; A M Pulichino; T Lamonerie; Y Gauthier; T Brue; A Enjalbert; J Drouin
Journal:  Cell       Date:  2001-03-23       Impact factor: 41.582

5.  Phenotypic homogeneity and genotypic variability in a large series of congenital isolated ACTH-deficiency patients with TPIT gene mutations.

Authors:  C Couture; A Saveanu; A Barlier; J C Carel; M Fassnacht; C E Flück; M Houang; M Maes; F Phan-Hug; A Enjalbert; J Drouin; T Brue; S Vallette
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

6.  RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway.

Authors:  Suihai Wang; Xiang Huang; Yue Li; Haimiao Lao; Ying Zhang; Huimin Dong; Weiwen Xu; Ji-Liang Li; Ming Li
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.425

7.  Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.

Authors:  Zhong Y Yeow; Bramwell G Lambrus; Rebecca Marlow; Kevin H Zhan; Mary-Anne Durin; Lauren T Evans; Phillip M Scott; Thao Phan; Elizabeth Park; Lorena A Ruiz; Daniela Moralli; Eleanor G Knight; Luned M Badder; Daniela Novo; Syed Haider; Catherine M Green; Andrew N J Tutt; Christopher J Lord; J Ross Chapman; Andrew J Holland
Journal:  Nature       Date:  2020-09-09       Impact factor: 49.962

8.  TRIM65-catalized ubiquitination is essential for MDA5-mediated antiviral innate immunity.

Authors:  Xueting Lang; Tiantian Tang; Tengchuan Jin; Chen Ding; Rongbin Zhou; Wei Jiang
Journal:  J Exp Med       Date:  2016-12-28       Impact factor: 14.307

9.  Pituitary cell translation and secretory capacities are enhanced cell autonomously by the transcription factor Creb3l2.

Authors:  Konstantin Khetchoumian; Aurélio Balsalobre; Alexandre Mayran; Helen Christian; Valérie Chénard; Julie St-Pierre; Jacques Drouin
Journal:  Nat Commun       Date:  2019-09-03       Impact factor: 14.919

10.  Structural insights into the TRIM family of ubiquitin E3 ligases.

Authors:  Yang Li; Han Wu; Wei Wu; Wei Zhuo; Weixiao Liu; Yixiao Zhang; Minzhang Cheng; Ye-Guang Chen; Ning Gao; Hongtao Yu; Linfang Wang; Wei Li; Maojun Yang
Journal:  Cell Res       Date:  2014-04-11       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.